帕唑帕尼与贝伐珠单抗交替方案治疗初治转移性透明细胞肾细胞癌:多中心单臂1/2期试验
该研究为单臂1/2期试验,评估帕唑帕尼与贝伐珠单抗交替方案治疗初治转移性透明细胞肾细胞癌。1期确定推荐2期剂量为帕唑帕尼800mg每日(第1-28天)联合贝伐珠单抗10mg/kg(第36和50天),10周为一周期。
要点
- 推荐2期剂量:帕唑帕尼800mg每日联合贝伐珠单抗10mg/kg,10周周期。
- 常见3-4级治疗相关不良事件为高血压(34%)、AST升高(12%)、ALT升高(17%)。
核心结论
- 1期确定了安全推荐2期剂量,2期显示该交替方案在初治转移性透明细胞肾细胞癌(以 favourable risk 为主)中具有 promising 抗肿瘤活性。
- 需3期随机对照试验数据确认这些发现。
研究设计与样本
- 单臂1/2期试验,在美国五个学术癌症中心进行。
- 1期纳入25例患者(允许既往最多一种高剂量IL-2或抗PD-1单药/联合CTLA-4抑制剂治疗),其中18例可评估剂量限制毒性。
- 2期纳入53例初治转移性透明细胞肾细胞癌患者,51例可评估活性(包括6例来自1期),59例可评估安全性。
- 2期患者中36例(71%)男性,15例(29%)女性;48例(94%)白人;33例(65%)按IMDC分类为 favourable risk。
主要发现
- 1期确定推荐2期剂量为帕唑帕尼800mg每日(第1-28天)联合贝伐珠单抗10mg/kg(第36和50天),10周为一周期。
- 最常见的3-4级治疗相关不良事件为高血压(20/59,34%)、天冬氨酸转氨酶升高(7/59,12%)和丙氨酸转氨酶升高(10/59,17%)。
- 5例(8%)患者因药物相关严重不良事件停止研究,无治疗相关死亡。
关键数值与推荐
- 2期主要终点为中位无进展生存期,由盲法中心统计师评估。
临床怎么用
- 该交替方案可作为初治转移性透明细胞肾细胞癌(尤其 favourable risk)的一种潜在治疗选择,但需3期随机试验确认。
- 治疗期间需监测高血压和肝功能(转氨酶)。
局限性
- 单臂设计,无随机对照,结论需3期随机对照试验验证。
- 2期样本量较小(51例可评估活性),且以 favourable risk 患者为主(65%),白人占94%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: VEGFR tyrosine kinase inhibitors (TKIs) are considered the backbone for the treatment of metastatic clear-cell renal cell carcinoma. We hypothesise that the administration of bevacizumab during scheduled breaks in pazopanib (TKI) treatment can improve tolerability and prolong progression-free survival compared with historical controls. METHODS: In this single-arm, phase 1/2 trial in five US academic cancer centres, patients (aged ≥18 years) with histologically confirmed metastatic clear-cell renal cell carcinoma, Eastern Cooperative Oncology Group performance status of 1 or less, and adequate organ functions were included. The phase 1 portion included patients with up to one previous therapy with high-dose IL-2 or an anti-PD-1 compound alone or in combination with a CTLA-4 inhibitor. The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma. The primary endpoint of phase 1 was to find the recommended phase 2 dose (RP2D). We tested a novel regimen using four dose levels: oral pazopanib (600 or 800 mg daily on days 1-28, followed by a 7 day break) alternating with intravenous bevacizumab (5, 7·5, or 10 mg/kg, one on day 36 and one on day 50) on a 10-week cycle in patients with metastatic clear-cell renal cell carcinoma naive to TKI treatment. The primary endpoint of phase 2 was median progression-free survival, assessed by a masked central statistician review. Dose selection (in patients who had completed 15 weeks) and activity (in patients who had completed one full 10-week cycle of the novel regimen) were analysed in the per-protocol population. Safety analyses included all patients who received any treatment. This trial was registered with ClinicalTrials.gov (NCT01684397) and is ongoing but closed to new participants. FINDINGS: Between Nov 21, 2012, and June 11, 2018, phase 1 enrolled 25 patients, with 18 patients evaluable for dose-limiting toxicity during the extended 15-week safety assessment period. The RP2D was established as pazopanib 800 mg daily (days 1-28) and bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle. Between Jan 23, 2019, and Oct 19, 2023, phase 2 enrolled 53 patients, of whom 51 (including six from phase 1) were evaluable for activity and 59 were evaluable for safety. 36 (71%) patients were male and 15 (29%) were female, and 48 (94%) patients were White. 33 (65%) patients in phase 2 had favourable risk per the International Metastatic Renal Cell Carcinoma Database Consortium categories. After a median follow-up of 63·7 months (IQR 16·2-73·5), median progression-free survival was 24·8 months (95% CI 17·2-34·3). The most common grade 3-4 treatment-related adverse events were hypertension (20 [34%] of 59) and elevated aspartate aminotransferase (seven [12%]) and alanine aminotransferase (ten [17%]). Five (8%) patients discontinued the study for drug-related serious adverse events. No treatment-related deaths occurred. INTERPRETATION: The phase 1 portion identified the safe RP2D. The phase 2 portion showed that this novel regimen has promising antitumour activity in patients with metastatic clear-cell renal cell carcinoma in the predominantly favourable risk group who are naive to treatment. Phase 3 randomised controlled trial data are needed to confirm these findings. FUNDING: The Roswell Park Comprehensive Cancer Center (RPCCC), US National Cancer Institute (NCI), Novartis.
引用
- George S, Vaishampayan U, Hutson A, et al. Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial. Lancet Oncol. 2026. PMID: 42945979. doi:10.1016/S1470-2045(26)00394-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。